Some folks’s genes affect how a lot weight they’ll lose and what unintended effects they’ll expertise whereas taking GLP-1 medicine, equivalent to Ozempic and Zepbound.
The genetic testing firm 23andMe carried out a research of greater than 27,000 prospects who have been taking GLP-1 medicine. Such medicine work by mimicking the motion of GLP-1, a hormone that helps regulate blood sugar and urge for food. Individuals who carry a specific genetic variant of the GLP-1 receptor gene GLP1R misplaced extra weight than those that don’t carry that variant, researchers report April 8 in Nature.
“The outcomes that we received made good organic sense,” says statistical geneticist Adam Auton, vice chairman of human genetics on the 23andMe Analysis Institute in Palo Alto, Calif. That’s as a result of the receptor is the goal of GLP-1 mimicking medicine. The variant the researchers discovered could enhance the quantity of the receptor protein on the cell floor, giving the drug extra targets, Auton says.
Individuals who have one copy of the variant misplaced an extra 0.76 kilograms (1.7 kilos) over about eight months, whereas these with two copies of the variant misplaced about 1.5 kgs (3.3 kilos) greater than these with out the variant. That variant accounts for about 10 % of the distinction in weight reduction folks expertise on the medicine.
“It’s a small contribution to the burden distinction among the many sufferers, however it’s necessary due to the importance of this gene,” says Andres Acosta, a doctor scientist on the Mayo Clinic in Rochester, Minn. Acosta was not concerned within the new research however is a cofounder of Phenomix Sciences, an organization headquartered in Menlo Park, Calif., that gives AI-powered genetic assessments to foretell which weight reduction drugs will work finest for a affected person.
The identical genetic variant discovered to influence weight reduction additionally will increase the chance that somebody taking a GLP-1 drug will develop nausea and vomiting, the researchers found. That’s not at all times a foul factor, Auton says. “If you happen to’re experiencing unintended effects of nausea and vomiting, which will truly be a signature that the medicine is having an impact.”
Individuals taking tirzepatide, bought underneath the brand-name Zepbound, have been extra more likely to have nausea and vomiting if they’d a selected variant of a special gene referred to as GIPR. The protein it makes is the goal of GIP, one other hormone concerned in blood sugar and urge for food management. The GIPR variant didn’t have a discernable impact on weight.
Not like semaglutide medicine Wegovy and Ozempic, tirzepatide targets each the GLP-1 and GIP receptors. And individuals who have variants in each the GLP1R and GIPR genes have almost 15 occasions elevated odds of vomiting when taking tirzepatide, the group discovered.
Genetics alone doesn’t decide how properly the medicine will work, Auton says. However realizing which variants an individual carries, he says, “could be fairly informative for people who’re contemplating these drugs. It might assist them put together themselves for the kind of expertise that they might have.”
